| pubmed-article:20602338 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:20602338 | lifeskim:mentions | umls-concept:C0035647 | lld:lifeskim |
| pubmed-article:20602338 | lifeskim:mentions | umls-concept:C0027396 | lld:lifeskim |
| pubmed-article:20602338 | lifeskim:mentions | umls-concept:C2347938 | lld:lifeskim |
| pubmed-article:20602338 | lifeskim:mentions | umls-concept:C0762662 | lld:lifeskim |
| pubmed-article:20602338 | lifeskim:mentions | umls-concept:C0687742 | lld:lifeskim |
| pubmed-article:20602338 | lifeskim:mentions | umls-concept:C0205345 | lld:lifeskim |
| pubmed-article:20602338 | lifeskim:mentions | umls-concept:C0185125 | lld:lifeskim |
| pubmed-article:20602338 | lifeskim:mentions | umls-concept:C0034384 | lld:lifeskim |
| pubmed-article:20602338 | lifeskim:mentions | umls-concept:C1705117 | lld:lifeskim |
| pubmed-article:20602338 | pubmed:issue | 11 | lld:pubmed |
| pubmed-article:20602338 | pubmed:dateCreated | 2010-10-27 | lld:pubmed |
| pubmed-article:20602338 | pubmed:abstractText | To undertake a quantitative benefit-risk analysis of rofecoxib relative to naproxen using an incremental net-benefit (INB) analysis from the societal perspective, using the same data evaluated by the Health Canada and US FDA expert advisory panels. | lld:pubmed |
| pubmed-article:20602338 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20602338 | pubmed:language | eng | lld:pubmed |
| pubmed-article:20602338 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20602338 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:20602338 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20602338 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20602338 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20602338 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20602338 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20602338 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20602338 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:20602338 | pubmed:month | Nov | lld:pubmed |
| pubmed-article:20602338 | pubmed:issn | 1099-1557 | lld:pubmed |
| pubmed-article:20602338 | pubmed:author | pubmed-author:MarraCarlo... | lld:pubmed |
| pubmed-article:20602338 | pubmed:author | pubmed-author:LyndLarry DLD | lld:pubmed |
| pubmed-article:20602338 | pubmed:author | pubmed-author:SadatsafaviMo... | lld:pubmed |
| pubmed-article:20602338 | pubmed:author | pubmed-author:NajafzadehMeh... | lld:pubmed |
| pubmed-article:20602338 | pubmed:copyrightInfo | Copyright © 2010 John Wiley & Sons, Ltd. | lld:pubmed |
| pubmed-article:20602338 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:20602338 | pubmed:volume | 19 | lld:pubmed |
| pubmed-article:20602338 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:20602338 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:20602338 | pubmed:pagination | 1172-80 | lld:pubmed |
| pubmed-article:20602338 | pubmed:dateRevised | 2011-2-9 | lld:pubmed |
| pubmed-article:20602338 | pubmed:meshHeading | pubmed-meshheading:20602338... | lld:pubmed |
| pubmed-article:20602338 | pubmed:meshHeading | pubmed-meshheading:20602338... | lld:pubmed |
| pubmed-article:20602338 | pubmed:meshHeading | pubmed-meshheading:20602338... | lld:pubmed |
| pubmed-article:20602338 | pubmed:meshHeading | pubmed-meshheading:20602338... | lld:pubmed |
| pubmed-article:20602338 | pubmed:meshHeading | pubmed-meshheading:20602338... | lld:pubmed |
| pubmed-article:20602338 | pubmed:meshHeading | pubmed-meshheading:20602338... | lld:pubmed |
| pubmed-article:20602338 | pubmed:meshHeading | pubmed-meshheading:20602338... | lld:pubmed |
| pubmed-article:20602338 | pubmed:meshHeading | pubmed-meshheading:20602338... | lld:pubmed |
| pubmed-article:20602338 | pubmed:meshHeading | pubmed-meshheading:20602338... | lld:pubmed |
| pubmed-article:20602338 | pubmed:meshHeading | pubmed-meshheading:20602338... | lld:pubmed |
| pubmed-article:20602338 | pubmed:year | 2010 | lld:pubmed |
| pubmed-article:20602338 | pubmed:articleTitle | A quantitative evaluation of the regulatory assessment of the benefits and risks of rofecoxib relative to naproxen: an application of the incremental net-benefit framework. | lld:pubmed |
| pubmed-article:20602338 | pubmed:affiliation | Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada. larry.lynd@ubc.ca | lld:pubmed |
| pubmed-article:20602338 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:20602338 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:20602338 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
